This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

GIOTRIF® has a manageable AE profile with dose modification proven to reduce AEs without compromising efficacy

GIOTRIF® has a manageable AE profile with dose modification proven to reduce AEs without compromising efficacy

*A grouped term.

Request contact
from Boehringer Ingelheim

References

  1. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.
  2. Park K et al. Lancet Oncol. 2016;17(5):577-589.
  3. Hirsch V et al. Poster #369 presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 3-7 June 2016.
  4. Yang JCH et al. Ann Oncol. 2016;27(11):2103-2110.

Report an adverse event

If you wish to report an adverse event (AE) after treatment with one of our products, please select your site from the link below. This will allow reporting of AEs in line with the reporting procedure effective in your country for reporting.

Boehringer Ingelheim local websites
Back to top